IGTP and DevsHealth join forces to develop new antibiotics against hospital-acquired infections by multi-resistant Staphylococcus aureus

DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.

- Innovation, Research

Progress in developing specific immunotherapies for type 1 diabetes

Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.

Innomed programme kicks off

The Innomed programme has been launched with the ambition of transforming the landscape of health innovation at the Can Ruti Campus, creating synergies between the public and private sectors. With a structured approach around three key axes - nurturing the culture of innovation, fostering project incubation, and facilitating cross-sector collaboration - Innomed aims to turn knowledge into action to achieve tangible impact on the healthcare community.

- Innovation

Nimble Diagnostics secures a €2.5 million grant from the EIC Accelerator programme

Nimble Diagnostics has been awarded a €2.5 million grant from EIC Accelerator, a funding programme of the European Innovation Council and SMEs Executive Agency (EISMEA). This spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia - BarcelonaTech (UPC) and the University of Barcelona (UB), is among the 47 selected companies from 15 countries, chosen from a pool of 648 proposals.

Two projects from IGTP funded by ”la Caixa” Foundation to transition their innovative research from the laboratory to patients

The first urine test that detects kidney fibrosis as an alternative to kidney biopsies, an initiative from the IVECAT group, and a project applying artificial intelligence to rapidly categorise stroke patients and enhance their recovery chances, from the Neurovascular Research group, are two of the fifteen projects from Catalan research centres selected within the 2023 call of the new CaixaImpulse Healthcare Innovation programme.